American Academy of Ophthalmology. Coding Updates and Resources. Accessed June 28, 2021. https://www.aao.org/practice-management/coding/updates-resources
Asrani S, Robin AL, Serle JB, et al; MERCURY-1 Study Group. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248-257.
Beckers HJ, Schouten JS, Webers CA. Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:593-599.
Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee; Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye [published correction appears in Can J Ophthalmol. 2009 Aug;44(4):477]. Can J Ophthalmol. 2009;44 Suppl 1:S7-S93.
Fellman RL, Mattox C, Singh K, et al. American Glaucoma Society Position Paper: Microinvasive Glaucoma Surgery. Ophthalmol Glaucoma. 2020;3:1-6.
Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1-9.
Ichioka S, Manabe K, Tsutsui A, et al. Effect of toric intraocular lens implantation on visual acuity and astigmatism status in eyes treated with microhook ab interno trabeculotomy. J Glaucoma. 2021;30:94-100.
Joshi SR, Akat PB, Ramanand JB, et al. Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma. Indian J Ophthalmol. 2013;61:765-767.
Lee AJ, McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol. 2008;2:545-555.
Liebmann JM, Lee JK. Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. Am J Manag Care. 2017;23:S279-S292.
Myers JS, Vold S, Zaman F, et al. Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials. Clin Ophthalmol. 2014;8:643-652.
Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014;8:853-864.
Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59:S93-S96.
Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127.
Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99:738-745.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Jonathan S. Myers, MD

Chief, Glaucoma Service
Wills Eye Hospital
Associate Professor
of Ophthalmology
Sidney Kimmel Medical College
at Thomas Jefferson University
Philadelphia, Pennsylvania

Disclosures

Disclosure: Jonathan S. Myers, MD, has the following relevant financial relationships:
Advisor or consultant for: Aerie; Allergan; Avisi; Glaukos; Haag Streit; MicroOptx; Olleyes
Speaker or a member of a speakers bureau for: Aerie; Allergan; Haag Streit
Grants for clinical research from: Aerie; Allergan; Avisi; Diopsys; Equinox; Glaukos; Haag Streit; MicroOptx; Nicox; Olleyes; Santen
Stocks, stock options, or bonds from: Avisi; Olleyes

Daniel Lee, MD

Director, Glaucoma Research Center
Wills Eye Hospital
Assistant Professor
of Ophthalmology
Sidney Kimmel Medical College
at Thomas Jefferson University
Philadelphia, Pennsylvania

Disclosures

Disclosure: Daniel Lee, MD, has the following relevant financial relationships:
Advisor or consultant for: Allergan; Quidel
Speaker or a member of a speakers bureau for: Glaukos
Grants for clinical research from: Allergan; Equinox; Glaukos; Nicox; Olleyes; Santen

Editors

Kathy Merlo

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Kathy Merlo has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Associate Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, ELS, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

Advancing Glaucoma Treatment - Combination Therapy, MIGS, and Filtering Surgery: How Would You Proceed?

Authors: Jonathan S. Myers, MD; Daniel Lee, MD
CME Released: 7/29/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 7/29/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for ophthalmologists, primary care physicians, and optometrists.

The goal of this activity is to educate ophthalmologists, primary care physicians, and optometrists on how to identify the best treatment strategies for patients with glaucoma that is uncontrolled by first- or second-line therapy.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Guideline- and evidence-based approaches to glaucoma treatment
- Newer intraocular pressure-lowering therapies
Have greater competence related to
- Selecting the best treatment options for glaucoma

Disclosures

Faculty

Jonathan S. Myers, MD

Chief, Glaucoma Service
Wills Eye Hospital
Associate Professor
of Ophthalmology
Sidney Kimmel Medical College
at Thomas Jefferson University
Philadelphia, Pennsylvania

Disclosures

Disclosure: Jonathan S. Myers, MD, has the following relevant financial relationships:
Advisor or consultant for: Aerie; Allergan; Avisi; Glaukos; Haag Streit; MicroOptx; Olleyes
Speaker or a member of a speakers bureau for: Aerie; Allergan; Haag Streit
Grants for clinical research from: Aerie; Allergan; Avisi; Diopsys; Equinox; Glaukos; Haag Streit; MicroOptx; Nicox; Olleyes; Santen
Stocks, stock options, or bonds from: Avisi; Olleyes

Daniel Lee, MD

Director, Glaucoma Research Center
Wills Eye Hospital
Assistant Professor
of Ophthalmology
Sidney Kimmel Medical College
at Thomas Jefferson University
Philadelphia, Pennsylvania

Disclosures

Disclosure: Daniel Lee, MD, has the following relevant financial relationships:
Advisor or consultant for: Allergan; Quidel
Speaker or a member of a speakers bureau for: Glaukos
Grants for clinical research from: Allergan; Equinox; Glaukos; Nicox; Olleyes; Santen

Editors

Kathy Merlo

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Kathy Merlo has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Associate Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, ELS, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and WillsEye Hospital.

For Physicians

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  The Wills Eye Hospital designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Ophthalmology

CME

Advancing Glaucoma Treatment - Combination Therapy, MIGS, and Filtering Surgery: How Would You Proceed?

Authors: Jonathan S. Myers, MD; Daniel Lee, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 7/29/2021

Valid for credit through: 7/29/2022, 11:59 PM EST

processing....

Post-Assessment Survey

What did you learn from this activity? Please proceed to a brief survey.

Page 1 of 3

Post-Assessment Survey

CME Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Jonathan S. Myers, MD

Daniel Lee, MD

Editors

Kathy Merlo

Yoji Yamaguchi, MA, ELS

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME

Advancing Glaucoma Treatment - Combination Therapy, MIGS, and Filtering Surgery: How Would You Proceed?

Target Audience and Goal Statement

Disclosures

Faculty

Jonathan S. Myers, MD

Daniel Lee, MD

Editors

Kathy Merlo

Yoji Yamaguchi, MA, ELS

Content Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Advancing Glaucoma Treatment - Combination Therapy, MIGS, and Filtering Surgery: How Would You Proceed?

Post-Assessment Survey